FIM
TEVA icon

Freedom Investment Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Freedom Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32,990
Closed -$594K – 822
2024
Q3 		$594K Sell
32,990
-1,660
-5% -$29.1K 0.05% 377
2024
Q2 		$563K Buy
+34,650
New +$534K 0.05% 402
2021
Q1 		– Sell
-11,014
Closed -$106K – 909
2020
Q4 		$106K Sell
11,014
-6,608
-37% -$63.3K 0.01% 599
2020
Q3 		$159K Sell
17,622
-20,629
-54% -$218K 0.02% 515
2020
Q2 		$472K Buy
38,251
+16,870
+79% +$191K 0.05% 290
2020
Q1 		$260K Buy
21,381
+283
+1% +$2.9K 0.02% 551
2019
Q4 		$207K Buy
21,098
+5,654
+37% +$50.5K 0.02% 609
2019
Q3 		$106K Sell
15,444
-2,490
-14% -$19.1K 0.01% 662
2019
Q2 		$166K Sell
17,934
-1,967
-10% -$23.7K 0.01% 647
2019
Q1 		$312K Buy
19,901
+360
+2% +$6.35K 0.03% 505
2018
Q4 		$301K Sell
19,541
-1,428
-7% -$29.3K 0.02% 576
2018
Q3 		$476K Buy
20,969
+358
+2% +$8.31K 0.03% 532
2018
Q2 		$501K Buy
+20,611
New +$420K 0.03% 553
2017
Q3 		– Sell
-10,967
Closed -$364K – 1148
2017
Q2 		$364K Buy
10,967
+1,246
+13% +$38.6K 0.02% 695
2017
Q1 		$312K Sell
9,721
-1,147
-11% -$39.1K 0.02% 746
2016
Q4 		$394K Sell
10,868
-28,179
-72% -$1.13M 0.02% 576
2016
Q3 		$1.8M Buy
39,047
+6,047
+18% +$315K 0.12% 112
2016
Q2 		$1.66M Sell
33,000
-112
-0.3% -$5.96K 0.11% 108
2016
Q1 		$1.77M Buy
33,112
+90
+0.3% +$5.28K 0.13% 97
2015
Q4 		$2.17M Buy
33,022
+7,393
+29% +$457K 0.16% 72
2015
Q3 		$581K Buy
25,629
+10,601
+71% +$687K 0.06% 285
2015
Q2 		$888K Buy
15,028
+2,549
+20% +$157K 0.09% 179
2015
Q1 		$777K Sell
12,479
-3,770
-23% -$219K 0.09% 191
2014
Q4 		$935K Buy
16,249
+8,956
+123% +$499K 0.12% 141
2014
Q3 		$392K Buy
7,293
+755
+12% +$40K 0.07% 277
2014
Q2 		$343K Sell
6,538
-8,063
-55% -$412K 0.06% 304
2014
Q1 		$771K Buy
14,601
+9,131
+167% +$422K 0.16% 104
2013
Q4 		$219K Buy
5,470
+90
+2% +$3.54K 0.05% 368
2013
Q3 		$203K Sell
5,380
-444
-8% -$17.3K 0.06% 331
2013
Q2 		$228K Buy
+5,824
New +$227K 0.08% 245

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Freedom Investment Management's TEVA Position: Q4 2024 in Review

Freedom Investment Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2024, closing a stake of 32,990 shares — an estimated $594K sold.

Freedom Investment Management first reported a position in TEVA in Q2 2013 and held it in 30 quarters. The position peaked at $2.17M in Q4 2015. 584 funds tracked by Wall St. Rank hold TEVA as of Q4 2024.

  • Freedom Investment Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2024 after selling out during the quarter.
  • Freedom Investment Management sold 32,990 Teva Pharmaceutical Industries Limited shares in Q4 2024, an estimated $594K.
  • Freedom Investment Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and held it in 30 quarters.
  • Freedom Investment Management's Teva Pharmaceutical Industries Limited position peaked at $2.17M in Q4 2015.
  • 584 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2024.

Based on Freedom Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.